ACTIN Report

PATIENT
ACTN-01-02-9999

REPORT DATE
10-Mar-2022

Sample ID: **ACTN01029999T** | Gender: **Male** | Birth year: **1950** | WHO: **1**

Tumor: **Skin - Melanoma** | Lesions: **Abdominal, CNS, Liver, Pulmonal** | Stage: **IV**

Summary

Patient clinical history (28-Feb-2022)

Relevant systemic treatment history	**Vemurafenib (3/2021), Ipilimumab (2022)**
Other oncological history	**Resection (2020)**
	Previous primary tumor: Bone/Soft tissue Schwannoma (3/2019, considered active)
Relevant non-oncological history	**Pancreatitis, Myocardial infarction**

Molecular results

Previous relevant molecular results	**ERBB2 3 + (IHC)**

WGS molecular results (05-Mar-2022)

Biopsy location	**Liver**
Events with approved treatment evidence in evidence	**BRAF V600E, High TML**
Events with trial eligibility in local database	**BRAF V600E, High TML**
Additional events with experimental evidence (evidence)	**None**
Additional events with other responsive evidence in evidence	**None**
Events with resistance evidence in evidence	**BRAF V600E: Erlotinib**

Approved treatments considered eligible

Treatment
Not yet determined

local trials and cohorts considered potentially eligible (1)

Trial ID	Acronym	Cohort	Cohort open?
Test Trial	TEST-TRIAL	Cohort B	Yes

ACTIN Report

PATIENT
ACTN-01-02-9999

REPORT DATE
10-Mar-2022

Clinical Details

Patient current details (28-Feb-2022)

Unresolved toxicities grade => 2	**Fatigue (2), Dizziness**
Significant aberration on latest ECG	**Atrial arrhythmia**
Cancer-related complications	**Ascites**
Known allergies	**Wasps (Environment), Pembrolizumab (Medication)**
Recent surgeries	**08-Feb-2022**

Tumor details (28-Feb-2022)

Measurable disease	**Yes**
CNS lesion status	**CNS (active)**
Brain lesion status	**No known brain lesions**

Laboratory results (28-Feb-2022)

Liver function	Total bilirubin		
	ASAT	(< 33 U/L)	**36 U/L (no trend information available)**
	ALAT		
	ALP		
	Albumin		
Kidney function	Creatinine		
	CKD-EPI eGFR	(> 100 mL/min)	**> 100 mL/min (08-Feb-2022)**
Other	Hemoglobin	(6.5 - 9.5 mmol/L)	**5.5 mmol/L (no trend information available)**
	Thrombocytes	(155 - 350 10^9/L)	**150 10^9/L (out of range for 2 cons. measurements, trend down)**
	LDH	(< 245 U/L)	**240 U/L (18-Feb-2022)**

Medication details

Medication	Categories	Start date	Stop date	Active?	Dosage	Frequency
Ibuprofen	NSAIDs	08-Feb-2022	25-Mar-2022	Yes	750 - 1000 mg	1 / day

Blood transfusions

Product	Date
Thrombocyte concentrate	23-Feb-2022

ACTIN Report

PATIENT
ACTN-01-02-9999

REPORT DATE
10-Mar-2022

Trial Matching Summary

Trial counts

Trials evaluated	**1**
Cohorts evaluated	**3**

Evaluation results per trial & cohort

Trial / Cohort	# Criteria	# Pass	# Warn	# Fail	# Undet.	# No eval
Test Trial (TEST-TRIAL)	3	2	0	0	0	1
Test Trial - Cohort A	1	0	0	1	0	0
Test Trial - Cohort B	0	0	0	0	0	0
Test Trial - Cohort C	0	0	0	0	0	0

ACTIN Report

PATIENT
ACTN-01-02-9999

REPORT DATE
10-Mar-2022

Trial Matching Details

Potentially eligible trials & cohorts

Test Trial

Evaluation	**PASS**
Acronym	**TEST-TRIAL**
Title	**This is an ACTIN test trial**

Rule	Reference	Evaluation
I-01	Is adult	PASS pass
E-01	This rule has 2 conditions: 1. Patient has no active brain metastases. 2. Patient has exhausted SOC.	NOT_EVALUATED pass

Test Trial - Cohort A

Cohort ID	**A**
Evaluation	**FAIL**
Open for inclusion?	**Yes**

Rule	Reference	Evaluation
I-02	Has no active CNS metastases	FAIL fail

Test Trial - Cohort B

Cohort ID	**B**
Evaluation	**PASS**
Open for inclusion?	**Yes**

Test Trial - Cohort C

Cohort ID	**C**
Evaluation	**PASS**
Open for inclusion?	**Yes**
Blacklisted for eligibility?	**Yes**